Italy-wide database study for adults with primary biliary cholangitis
Part of Digestive system clinical trials.
This study creates a national registry (database) of adults in Italy living with primary biliary cholangitis (PBC). Being included can help doctors better understand the condition and improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary biliary cholangitis (PBC).
- You are 18 years or older.
- You live in Italy.
- You meet the usual medical definition of PBC (for example, abnormal liver bile tests and/or certain antibody tests, or specific biopsy findings).
- You are willing to participate (you must not refuse).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a registry study that collects health information from people with primary biliary cholangitis (PBC), a rare liver disease where the immune system damages bile ducts. By joining, you help researchers better understand PBC and improve care for patients with this condition.
This study follows adults with primary biliary cholangitis (a long-term liver and bile duct condition). It may help doctors better understand the disease in different people, including those identified by specific blood antibody tests.
This trial is testing a “find patients who are missing from care” program for people with primary biliary cholangitis (PBC). It may help connect you to follow-up sooner if you’ve been hard to reach through usual clinic records.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial tracks how well the combination of ursodiol and seladelpar works in people with primary biliary cholangitis (PBC), a liver disease. It aims to see if this treatment helps control symptoms and liver function.
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.